

# ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that its first therapeutic mRNA candidate from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics") has demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. The Company is planning follow-up studies to confirm the anti-cancer effect as well as to further characterize the mechanism of action of the lead mRNA candidate. Given the encouraging results, the Company has decided to expand on its therapeutic mRNA research and development program.

"We are pleased with the initial in vivo efficacy results of our first therapeutic mRNA candidate. The speed at which the Company was able to go from an idea to in vivo results is a testament to the promise of mRNA as a therapeutic modality to treat cancer, autoimmunity, and inflammatory diseases. The Company has decided to commit more resources to therapeutic mRNA development and is already working on ways to drive mRNA expression in a cell-type or location-specific manner to increase therapeutic efficacy and reduce any potential systemic toxicity of therapeutic mRNA delivery." said Salim Dhanji, PhD, Chief Executive Officer of ME Therapeutics.

Myeloid Enhancement (ME) Therapeutics is a preclinical stage, Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, please visit <http://www.metherapeutics.com> and the Company's profile on SEDAR+ at <http://www.sedarplus.ca>.

## ON BEHALF OF THE BOARD

### **"Salim Dhanji"**

Dr. Salim Dhanji  
Chief Executive Officer and Director

For further information, please contact:

Dr. Salim Dhanji  
Telephone: (236) 516-7714

*Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### **Cautionary Statement Regarding Forward-Looking Statements**

*This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's collaborations, research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to*

*differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that future research does not support continued development, that regulatory approvals are not obtained or maintained, that challenges related to mRNA technology development, including delivery, stability, or efficacy issues cannot be overcome, that the Company relies on third-party collaborators and vendors for certain aspects of the research, that the research will not be completed within the expected timeline, that the Company is unable to obtain intellectual property protection for the results, that the Company may require additional funding to advance its research and develop its business, and that the Company's business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.*



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/237141>